Health Discovery, NeoGenomics Sign Cancer Testing License Pact | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostic technologies developer Health Discovery said today that it has licensed some of its biomarker-based testing tools for hematopoietic and solid tumor cancers to NeoGenomics for $1 million in cash, 1.4 million shares in NeoGenomics stock, milestone payments of up to $5 million, and ensuing royalties.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.